- FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended<figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…BioPharma Dive · 2mo ago↗ source
- Lilly, Gilead lead pharma’s M&A boom<figure><div><img src="https://imgproxy.divecdn.com/wW2Sw-v1m2RoAnzb6Llg6MP71MxLlDb61aNlxns-F98/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjIxODc5NzA5X2RKS…BioPharma Dive · 2mo ago↗ source
- 'Pharma, not really’: Top young AI talent shuns careers at big drugmakersRIO DE JANEIRO — Mazdak Abulnaga should be the poster child for the type of employee pharma companies want to hire this year. Abulnaga, a 33-year-old postdoctoral fellow at MIT and Harvard Medica…